

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.23AUS2APPLICATION NO.
09/929,955INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Sällberg et al.FILING DATE
August 15, 2001GROUP
1648

(2002) SEVERAL SHEETS IF NECESSARY

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BOL	1	EP 0 388 232	09/19/90	European Patent Office	/	/		
	2	EP 0 414 475	02/27/91	European Patent Office	/	/		
	3	WO 91/15575	10/17/91	WIPO	/	/		
	4	WO 92/19743	11/12/92	WIPO	/	/		
	5	WO 93/00365	01/07/93	WIPO	/	/		
	6	WO 93/06126	04/01/93	WIPO	/	/		
	7	WO 94/16737	08/07/94	WIPO	/	/		
	8	EP 0 450 931	06/12/96	European Patent Office	/	/		
	9	WO 97/12043	04/03/97	WIPO	/	/		
	10	EP 0 543 924	06/18/97	European Patent Office	/	/		
	11	EP 0 842 947	05/20/98	European Patent Office	/	/		
	12	EP 0 693 687	07/28/99	European Patent Office	/	/		
	13	EP 0 556 292	12/29/99	European Patent Office	/	/		
	14	EP 1 034 785	09/13/00	European Patent Office	/	/		
	15	EP 0 318 216	08/29/01	European Patent Office	/	/		
	16	EP 0 398 748	01/09/02	European Patent Office	/	/		
	17	WO 02/13855	02/21/02	WIPO	/	/		
	18	WO 02/14362	02/21/02	WIPO	/	/		

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

BOL	19	Chen et al., "Human and Murine Antibody Recognition is Focused on the ATPase/Helicase, but not the Protease Domain of the Hepatitis C Virus Nonstructural 3 Protein," <i>Hepatology</i> , 28(1):219-224 (1998).
BOL	20	Chen et al., "Detection of Hepatitis C Virus RNA in the Cell Fraction of Saliva Before and After Oral Surgery," <i>J. Med. Virol.</i> , 43:223-226 (1995).

EXAMINER

Bargun L.

DATE CONSIDERED

07/23/2003

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED
OCT 09 2002
TECH CENTER 1600/2300

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
TRIPEP.23AUS2APPLICATION NO.
09/929,955INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Sällberg et al.FILING DATE
August 15, 2001GROUP
1648

SEE SEVERAL SHEETS IF NECESSARY

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

BOL	21	Cramp et al., "Hepatitis C Virus-Specific T-Cell Reactivity During Interferon and Ribavirin Treatment in Chronic Hepatitis C," <i>Gastron. Enterol.</i> , 118:346-355 (2000)
	22	Diepolder et al., "Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection," <i>Lancet</i> , 346(8981):1006-1007.
	23	Gordon et al., "Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations," <i>Journal of Infectious Diseases</i> , 181(1):42-50.
	24	Huffman et al., "In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses," <i>Antimicrob. Agents. Chemother.</i> , 3(2):235 (1973).
	25	Jin et al., "Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA Helicase," <i>Arch. Biochem. Biophys.</i> , 323:47-53 (1995).
	26	Kakumu et al., "Pilot Study of Ribavirin and Interferon- for Chronic Hepatitis B," <i>Hepatology</i> , 18(2):258-263 (1993).
	27	Kato, "Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation," <i>Microb. Com. Genomics</i> , 5(3):129-151 (2000).
	28	Kwong et al., "Hepatitis C virus NS3/4A protease," <i>Antiviral Res.</i> , 41(1):67-84 (1999).
	29	Kwong et al., "Structure and function of hepatitis C virus NS3 helicase," <i>Curr. Top. Microbiol. Immunol.</i> , 242:171-196 (2000).
	30	Lawrence et al., "Advances in the treatment of hepatitis C," <i>Adv. Intern. Med.</i> , 45:65-105 (2000).
	31	Li et al., "Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation," <i>Science</i> , 288:2219-2222 (2000).
	32	Marquardt et al., "Ribavirin inhibits mast cell mediator release," <i>J. Pharmacol. Exp. Therapeutics</i> , 240(1):145-149 (1987).
	33	Marshall et al., "Detection of HCV RNA by the asymmetric gap ligase chain reaction," <i>PCR Methods and Applications</i> , 4(2):80-84 (1994).
	34	Missale et al., "Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response," <i>J. Clin. Invest.</i> , 98(3):706-714 (1996).
	35	Neuberger et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> , 312:604-608 (1984).
	36	Pape et al., "Role of the specific T-cell response for clearance and control of hepatitis C virus," <i>J. Viral. Hepat.</i> , Supp. 6, 1:36-40 (1999).
	37	Peavy et al., "Inhibition of murine plaque-forming cell responses in vivo by ribavirin," <i>J. Immunology</i> , 126(3):861-864 (1981).
	38	Powers et al., "Selective inhibition of functional lymphocyte subpopulations by ribavirin," <i>Antimicrob. Agents. Chemother.</i> , 22(1):108-114 (1982).
	39	Sällberg et al., "Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens," <i>Journal of Virology</i> , 71:5295-5303 (1997).
	40	Sällberg, "A Hepatitis C Virus Non-Structural NS3/4A Fusion Gene," U.S. Patent Application Serial No. 09/930,591, filed August 15, 2001.
	41	Sällberg and Hultgren, "Vaccines Containing Ribavirin and Methods of use Thereof," U.S. Patent Application Serial No. 10/104,966, filed March 22, 2002.
	42	Sidwell et al., "Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide," <i>Science</i> , 177(50):705-706 (1972).
	43	Smith et al., "Molecular Engineering of the <i>Autographa californica</i> Nuclear Polyhedrosis Virus Genome: Deletion Mutations Within the Polyhedrin Gene," <i>Journal of Virology</i> , 46:584 (1983).
	44	Szybalska and Szybalska, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait," <i>Proc Natl Acad Sci USA</i> , 48:2026 (1962).
✓	45	Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," <i>Nature</i> , 314:452-454 (1985).


EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

#6

SHEET 3 OF 3

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.23AUS2	APPLICATION NO. 09/929,955
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Sällberg et al.	
		FILING DATE August 15, 2001	GROUP 1648

OCT 09 2002
FBI CENTER 1600/2800

RECEIVED

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
BACi	46	Tan et al., "How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A," <i>Virology</i> , 284(1):1-12 (2001).
	47	Vaitukaitis et al., "A method for producing specific antisera with small doses of immunogen," <i>J. Clin. Endocrinology Metab.</i> , 33(6):988-991 (1971).
	48	Zhang et al., "Characterization of a monoclonal antibody and its singl-chain antibody fragment recognizing the nucleoside triphosphatase/helicase domain of the hepatitis C virus nonstructural 3 protein," <i>Clin. Diagn. Lab. Immunol.</i> , 7(1):58-63 (2000).
	49	Zhang et al., "Molecular basis for antibody cros-reactivity between the hepatitis C virs core protein and the hos-derived GOR protein," <i>Clin. Exp. Immunol.</i> , 96(3):403-409 (1994).

S:\DOCS\DA\DAI-1720.DOC
091202

EXAMINER	<i>Daugun/hi</i>	DATE CONSIDERED	<i>07/23/2003</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			